LegoChem Biosciences Inc - Asset Resilience Ratio

Latest as of September 2025: 56.48%

LegoChem Biosciences Inc (141080) has an Asset Resilience Ratio of 56.48% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read LegoChem Biosciences Inc total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩395.06 Billion
≈ $267.73 Million USD Cash + Short-term Investments

Total Assets

₩699.43 Billion
≈ $473.99 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how LegoChem Biosciences Inc's Asset Resilience Ratio has changed over time. See LegoChem Biosciences Inc (141080) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down LegoChem Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 141080 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩395.06 Billion 56.48%
Total Liquid Assets ₩395.06 Billion 56.48%

Asset Resilience Insights

  • Very High Liquidity: LegoChem Biosciences Inc maintains exceptional liquid asset reserves at 56.48% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

LegoChem Biosciences Inc Industry Peers by Asset Resilience Ratio

Compare LegoChem Biosciences Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Fortress Biotech Inc
NASDAQ:FBIO
Biotechnology 11.59%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Biotechnology 0.58%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
BioArctic AB (publ)
ST:BIOA-B
Biotechnology 72.35%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%

Annual Asset Resilience Ratio for LegoChem Biosciences Inc (2014–2024)

The table below shows the annual Asset Resilience Ratio data for LegoChem Biosciences Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 49.44% ₩365.04 Billion
≈ $247.38 Million
₩738.38 Billion
≈ $500.39 Million
+21.79pp
2023-12-31 27.65% ₩52.40 Billion
≈ $35.51 Million
₩189.50 Billion
≈ $128.42 Million
+2.95pp
2022-12-31 24.71% ₩62.39 Billion
≈ $42.28 Million
₩252.53 Billion
≈ $171.14 Million
+4.11pp
2021-12-31 20.60% ₩60.39 Billion
≈ $40.93 Million
₩293.23 Billion
≈ $198.72 Million
-17.10pp
2020-12-31 37.70% ₩51.24 Billion
≈ $34.72 Million
₩135.91 Billion
≈ $92.11 Million
+4.45pp
2019-12-31 33.25% ₩47.03 Billion
≈ $31.87 Million
₩141.48 Billion
≈ $95.88 Million
-18.23pp
2018-12-31 51.48% ₩62.64 Billion
≈ $42.45 Million
₩121.69 Billion
≈ $82.47 Million
+25.31pp
2017-12-31 26.17% ₩21.52 Billion
≈ $14.58 Million
₩82.24 Billion
≈ $55.73 Million
-9.70pp
2016-12-31 35.87% ₩32.12 Billion
≈ $21.77 Million
₩89.55 Billion
≈ $60.69 Million
+11.53pp
2015-12-31 24.34% ₩16.66 Billion
≈ $11.29 Million
₩68.44 Billion
≈ $46.38 Million
-59.82pp
2014-12-31 84.16% ₩28.41 Billion
≈ $19.25 Million
₩33.76 Billion
≈ $22.88 Million
--
pp = percentage points

About LegoChem Biosciences Inc

KQ:141080 Korea Biotechnology
Market Cap
$4.52 Billion
₩6.68 Trillion KRW
Market Cap Rank
#3833 Global
#101 in Korea
Share Price
₩183400.00
Change (1 day)
-5.71%
52-Week Range
₩97000.00 - ₩213500.00
All Time High
₩213500.00
About

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more